LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

4.68 6.85

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.39

Max

4.75

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+70.45% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-62M 404M
Iepriekšējā atvēršanas cena	-2.17
Iepriekšējā slēgšanas cena	4.68

Ziņu noskaņojums

By Acuity

20%

80%

35 / 344 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. jūn. 21:51 UTC

Galvenie tirgus virzītāji

Merlin Shares Rally After Defense Department's Design Review Wraps

2026. g. 4. jūn. 23:46 UTC

Tirgus saruna

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026. g. 4. jūn. 23:44 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 4. jūn. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026. g. 4. jūn. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia to Enter Trading Halt

2026. g. 4. jūn. 23:34 UTC

Tirgus saruna

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 4. jūn. 23:08 UTC

Tirgus saruna

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026. g. 4. jūn. 22:41 UTC

Tirgus saruna

Australia Shares Set to Rise at the Open -- Market Talk

2026. g. 4. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026. g. 4. jūn. 20:16 UTC

Tirgus saruna

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026. g. 4. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026. g. 4. jūn. 19:46 UTC

Tirgus saruna

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026. g. 4. jūn. 19:38 UTC

Tirgus saruna

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026. g. 4. jūn. 19:30 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026. g. 4. jūn. 18:47 UTC

Iegādes, apvienošanās, pārņemšana

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026. g. 4. jūn. 18:38 UTC

Peļņas

Money Quote: Tech Weakness in Context -- WSJ

2026. g. 4. jūn. 18:24 UTC

Peļņas

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 17:09 UTC

Tirgus saruna

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026. g. 4. jūn. 16:58 UTC

Peļņas

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 16:46 UTC

Tirgus saruna

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026. g. 4. jūn. 16:38 UTC

Peļņas

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 4. jūn. 16:13 UTC

Tirgus saruna

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026. g. 4. jūn. 16:11 UTC

Tirgus saruna

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026. g. 4. jūn. 15:56 UTC

Tirgus saruna

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

70.45% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 70.45%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

35 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.